BioNTech (NASDAQ:BNTX) Price Target Cut to $138.00 by Analysts at HC Wainwright

BioNTech (NASDAQ:BNTX) had its target price reduced by HC Wainwright from $145.00 to $138.00 in a report issued on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for BioNTech’s Q4 2025 earnings at $0.51 EPS, Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.25) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at $0.88 EPS and FY2026 earnings at ($5.35) EPS.

A number of other research analysts have also weighed in on the company. Citigroup restated a “buy” rating and issued a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. BMO Capital Markets increased their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Wall Street Zen raised shares of BioNTech from a “sell” rating to a “hold” rating in a research note on Saturday, June 7th. Finally, JPMorgan Chase & Co. dropped their price target on BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a research report on Thursday, May 22nd. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.86.

BioNTech Stock Performance

BNTX opened at $104.40 on Monday. The firm’s fifty day simple moving average is $101.79 and its two-hundred day simple moving average is $107.84. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a market cap of $25.10 billion, a price-to-earnings ratio of -30.71 and a beta of 1.29. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC acquired a new position in BioNTech during the 1st quarter worth about $167,000. Millennium Management LLC lifted its position in shares of BioNTech by 252.5% during the first quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock worth $49,625,000 after purchasing an additional 390,360 shares in the last quarter. Banque Transatlantique SA purchased a new position in shares of BioNTech in the first quarter valued at approximately $80,000. Alyeska Investment Group L.P. grew its holdings in shares of BioNTech by 2,769.2% in the first quarter. Alyeska Investment Group L.P. now owns 75,000 shares of the company’s stock valued at $6,830,000 after purchasing an additional 72,386 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of BioNTech in the first quarter valued at approximately $455,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.